| Year |
Citation |
Score |
| 2023 |
Zhou B, Wang B, Zou F, Mei H, Liu Q, Qi S, Wang W, Jin R, Wang A, Chen Y, Liu F, Wang W, Liu J, Liu Q. Discovery of dihydropyridinone derivative as a covalent EZH2 degrader. European Journal of Medicinal Chemistry. 261: 115825. PMID 37826933 DOI: 10.1016/j.ejmech.2023.115825 |
0.316 |
|
| 2023 |
Hu C, Shen L, Zou F, Wu Y, Wang B, Wang A, Wu C, Wang L, Liu J, Wang W, Liu Q. Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy. Acta Pharmaceutica Sinica. B. 13: 3694-3707. PMID 37719386 DOI: 10.1016/j.apsb.2023.05.026 |
0.477 |
|
| 2023 |
Liang X, Deng M, Zou F, Qi Z, Wang C, Liu J, Liu Q, Wang B, Qi S, Ge J, Yu H, Wang A, Liu Q, Liu J. Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor. European Journal of Medicinal Chemistry. 260: 115768. PMID 37683362 DOI: 10.1016/j.ejmech.2023.115768 |
0.376 |
|
| 2023 |
Liang Q, Wang B, Zou F, Guo G, Wang W, Wang W, Liu Q, Shen L, Hu C, Wang W, Wang A, Huang T, He Y, Xia R, Ge J, ... ... Liu Q, et al. Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor. European Journal of Medicinal Chemistry. 256: 115411. PMID 37209613 DOI: 10.1016/j.ejmech.2023.115411 |
0.308 |
|
| 2023 |
Wang A, Liu J, Li X, Zou F, Qi Z, Qi S, Liu Q, Wang Z, Cao J, Jiang Z, Wang B, Ge J, Wang L, Wang W, Liu J, ... Liu Q, et al. Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment. European Journal of Pharmacology. 175752. PMID 37164118 DOI: 10.1016/j.ejphar.2023.175752 |
0.33 |
|
| 2023 |
Guo C, Zhang L, Zhao M, Ai Y, Liao W, Wan L, Liu Q, Li S, Zeng J, Ma X, Tang J. Targeting lipid metabolism with natural products: A novel strategy for gastrointestinal cancer therapy. Phytotherapy Research : Ptr. PMID 36748953 DOI: 10.1002/ptr.7735 |
0.305 |
|
| 2023 |
Mei H, Wu H, Yang J, Zhou B, Wang A, Hu C, Qi S, Jiang Z, Zou F, Wang B, Liu F, Chen Y, Wang W, Liu J, Liu Q. Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies. Signal Transduction and Targeted Therapy. 8: 18. PMID 36642705 DOI: 10.1038/s41392-022-01240-3 |
0.44 |
|
| 2022 |
Wang ZW, Zou FM, Wang AL, Yang J, Jin R, Wang BL, Shen LJ, Qi S, Liu J, Liu J, Wang WC, Liu QS. Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1. Acta Pharmacologica Sinica. PMID 36216899 DOI: 10.1038/s41401-022-00993-5 |
0.456 |
|
| 2022 |
Liang X, Wang C, Wang B, Liu J, Qi S, Wang A, Liu Q, Deng M, Wang L, Liu J, Liu Q. Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors. European Journal of Medicinal Chemistry. 243: 114782. PMID 36179404 DOI: 10.1016/j.ejmech.2022.114782 |
0.422 |
|
| 2022 |
Chen N, Qi Y, Ma X, Xiao X, Liu Q, Xia T, Xiang J, Zeng J, Tang J. Rediscovery of Traditional Plant Medicine: An Underestimated Anticancer Drug of Chelerythrine. Frontiers in Pharmacology. 13: 906301. PMID 35721116 DOI: 10.3389/fphar.2022.906301 |
0.311 |
|
| 2022 |
Cao JY, Qi S, Wu H, Wang AL, Liu QW, Li XX, Wang BL, Ge J, Zou FM, Chen C, Wang JJ, Hu C, Liu J, Wang WC, Liu QS. CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers. Acta Pharmacologica Sinica. PMID 35228653 DOI: 10.1038/s41401-022-00882-x |
0.355 |
|
| 2022 |
Liu J, Gao J, Wang A, Jiang Z, Qi S, Qi Z, Liu F, Yu K, Cao J, Chen C, Hu C, Wu H, Wang L, Wang W, Liu Q, et al. Nintedanib overcomes drug resistance from upregulation of FGFR signaling and imatinib-induced KIT mutations in gastrointestinal stromal tumors. Molecular Oncology. PMID 35194937 DOI: 10.1002/1878-0261.13199 |
0.359 |
|
| 2022 |
Yang J, Weisberg EL, Qi S, Ni W, Mei H, Wang Z, Meng C, Zhang S, Hou M, Qi Z, Wang A, Jiang Y, Jiang Z, Huang T, Liu Q, ... ... Liu Q, et al. Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. Leukemia. PMID 35034955 DOI: 10.1038/s41375-021-01494-w |
0.383 |
|
| 2021 |
Zhou B, Liang X, Mei H, Qi S, Jiang Z, Wang A, Zou F, Liu Q, Liu J, Wang W, Hu C, Chen Y, Wang Z, Wang B, Wang L, ... ... Liu Q, et al. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas. Journal of Medicinal Chemistry. PMID 34664960 DOI: 10.1021/acs.jmedchem.1c01154 |
0.341 |
|
| 2021 |
Lu T, Cao J, Zou F, Li X, Wang A, Wang W, Liang H, Liu Q, Hu C, Chen C, Hu Z, Wang W, Li L, Ge J, Shen Y, ... ... Liu Q, et al. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). European Journal of Pharmacology. 173944. PMID 33581133 DOI: 10.1016/j.ejphar.2021.173944 |
0.452 |
|
| 2020 |
Li F, Liang X, Jiang Z, Wang A, Wang J, Chen C, Wang W, Zou F, Qi Z, Liu Q, Hu Z, Cao J, Wu H, Wang B, Wang L, ... ... Liu Q, et al. Discovery of ()-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1-pyrazolo[3,4-]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. Journal of Medicinal Chemistry. PMID 33180507 DOI: 10.1021/acs.jmedchem.0c01544 |
0.351 |
|
| 2020 |
Ye Z, Wang Y, Wu H, Song T, Li X, Liu Q, Wang C. Chemoproteomic profiling of an Ibrutinib analogue reveals its unexpected role in DNA damage repair. Chembiochem : a European Journal of Chemical Biology. PMID 32979005 DOI: 10.1002/cbic.202000527 |
0.355 |
|
| 2020 |
Wang B, Zhang W, Liu X, Zou F, Wang J, Liu Q, Wang A, Hu Z, Chen Y, Qi S, Jiang Z, Chen C, Hu C, Wang L, Wang W, ... Liu Q, et al. Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. European Journal of Medicinal Chemistry. 207: 112744. PMID 32949955 DOI: 10.1016/J.Ejmech.2020.112744 |
0.542 |
|
| 2020 |
Liu J, Liang Q, Wang A, Zou F, Qi Z, Yu K, Liu Q, Chen C, Liu J, Liu Q. Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. Signal Transduction and Targeted Therapy. 5: 200. PMID 32929063 DOI: 10.1038/S41392-020-00309-1 |
0.339 |
|
| 2020 |
Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research. 37: 167. PMID 32778962 DOI: 10.1007/S11095-020-02851-7 |
0.603 |
|
| 2020 |
Fu L, Zou F, Liu Q, Wang B, Wang J, Liang H, Liang X, Liu J, Shi J, Liu Q. An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia. Nanomedicine : Nanotechnology, Biology, and Medicine. 102283. PMID 32777451 DOI: 10.1016/J.Nano.2020.102283 |
0.376 |
|
| 2020 |
Wang WL, Jiang ZR, Hu C, Chen C, Hu ZQ, Wang AL, Wang L, Liu J, Wang WC, Liu QS. Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacologica Sinica. PMID 32737469 DOI: 10.1038/S41401-020-0465-8 |
0.536 |
|
| 2020 |
Chen C, Cheng CD, Wu H, Wang ZW, Wang L, Jiang ZR, Wang AL, Hu C, Dong YF, Niu WX, Qi S, Qi ZP, Liu J, Wang WC, Niu CS, ... Liu QS, et al. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. Acta Pharmacologica Sinica. PMID 32398685 DOI: 10.1038/S41401-020-0418-2 |
0.541 |
|
| 2020 |
Chen C, Wang L, Li L, Wang A, Huang T, Hu J, Zhao M, Liu F, Qi S, Hu C, Wang W, Liu J, Ge J, Xia R, Wang W, ... Liu Q, et al. Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. Experimental Cell Research. 112054. PMID 32376287 DOI: 10.1016/J.Yexcr.2020.112054 |
0.316 |
|
| 2020 |
Wang A, Hu C, Chen C, Liang X, Wang B, Zou F, Yu K, Li F, Liu Q, Qi Z, Wang J, Wang W, Wang L, Weisberg EL, Wang W, ... ... Liu Q, et al. Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia. Haematologica. PMID 32299905 DOI: 10.3324/Haematol.2019.244186 |
0.423 |
|
| 2020 |
Jiang Z, Wang L, Liu X, Chen C, Wang B, Wang W, Hu C, Yu K, Qi Z, Liu Q, Wang A, Liu J, Hong G, Wang W, Liu Q. Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent. Acta Pharmaceutica Sinica. B. 10: 488-497. PMID 32140394 DOI: 10.1016/J.Apsb.2019.10.004 |
0.538 |
|
| 2020 |
Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. Correction: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The Journal of Biological Chemistry. 295: 2886. PMID 32111721 DOI: 10.1074/Jbc.Aac120.012837 |
0.764 |
|
| 2020 |
Wang W, Jiang Z, Wang L, Wang A, Liu J, Chen C, Yu K, Zou F, Wang W, Liu J, Liu Q. All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase. Cancer Letters. PMID 31904486 DOI: 10.1016/J.Canlet.2019.12.045 |
0.457 |
|
| 2019 |
Liang X, Jiang Z, Huang Z, Li F, Chen C, Hu C, Wang W, Hu Z, Liu Q, Wang B, Wang L, Qi Z, Liu J, Jiang L, Liu Q. Discovery of 6'-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium. European Journal of Medicinal Chemistry. 188: 112012. PMID 31911293 DOI: 10.1016/J.Ejmech.2019.112012 |
0.453 |
|
| 2019 |
Wang L, Hu C, Wang A, Chen C, Wu J, Jiang Z, Zou F, Yu K, Wu H, Liu J, Wang W, Wang Z, Wang B, Qi Z, Liu Q, ... ... Liu Q, et al. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models. Investigational New Drugs. PMID 31872348 DOI: 10.1007/S10637-019-00868-3 |
0.506 |
|
| 2019 |
Chopra SS, Jenney A, Palmer A, Niepel M, Chung M, Mills C, Sivakumaren SC, Liu Q, Chen JY, Yapp C, Asara JM, Gray NS, Sorger PK. Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. Cell Systems. PMID 31812693 DOI: 10.1016/J.Cels.2019.11.001 |
0.831 |
|
| 2019 |
Wu Y, Wang B, Wang J, Qi S, Zou F, Qi Z, Liu F, Liu Q, Chen C, Hu C, Hu Z, Wang A, Wang L, Wang W, Ren T, ... ... Liu Q, et al. Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors. Journal of Medicinal Chemistry. PMID 31250638 DOI: 10.1021/Acs.Jmedchem.9B00280 |
0.479 |
|
| 2019 |
Liu F, Zou F, Chen C, Yu K, Liu X, Qi S, Wu J, Hu C, Hu Z, Liu J, Liu X, Wang L, Ge J, Wang W, Ren T, ... ... Liu Q, et al. Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology. 11: 1758835919849757. PMID 31205508 DOI: 10.1177/1758835919849757 |
0.42 |
|
| 2019 |
Liu X, Wang B, Chen C, Qi Z, Zou F, Wang J, Hu C, Wang A, Ge J, Liu Q, Yu K, Hu Z, Jiang Z, Wang W, Wang L, ... ... Liu Q, et al. Discovery of (E)-N1-(3-fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). Journal of Medicinal Chemistry. PMID 31046271 DOI: 10.1021/Acs.Jmedchem.9B00176 |
0.474 |
|
| 2019 |
Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands NA, Liu Q, In GK, Peng D, Yuan W, Machida K, Yu M, Akbari O, et al. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nature Communications. 10: 1693. PMID 30979895 DOI: 10.1038/S41467-019-09634-8 |
0.378 |
|
| 2019 |
Gao L, Hu Y, Tian Y, Fan Z, Wang K, Li H, Zhou Q, Zeng G, Hu X, Yu L, Zhou S, Tong X, Huang H, Chen H, Liu Q, et al. Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition. Nature Communications. 10: 1665. PMID 30971692 DOI: 10.1038/S41467-019-09295-7 |
0.349 |
|
| 2019 |
Wu J, Wang A, Li X, Chen C, Qi Z, Hu C, Wang W, Wu H, Huang T, Zhao M, Wang W, Hu Z, Liu Q, Wang B, Wang L, et al. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML). Cancer Biology & Therapy. 1-9. PMID 30894066 DOI: 10.1080/15384047.2019.1579958 |
0.544 |
|
| 2019 |
Lu T, Chen C, Wang A, Jiang Z, Qi Z, Hu Z, Hu C, Liu F, Wang W, Wu H, Wang B, Wang L, Qi S, Wu J, Wang W, ... ... Liu Q, et al. Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models. Cancer Letters. PMID 30684595 DOI: 10.1016/J.Canlet.2019.01.024 |
0.373 |
|
| 2019 |
Li C, Sarotti AM, Wu X, Yang B, Turkson J, Chen Y, Liu Q, Cao S. An Unusual Benzoisoquinoline-9-one Derivative and Other Related Compounds with Antiproliferative Activity from Hawaiian Endophytic Fungus sp. FT431. Molecules (Basel, Switzerland). 24. PMID 30621059 DOI: 10.3390/Molecules24010196 |
0.304 |
|
| 2019 |
Chopra SS, Jenney A, Palmer A, Niepel M, Chung M, Mills C, Sivakumaren SC, Liu Q, Chen J, Yapp C, Gray NS, Sorger PK. Abstract B103: Torin2 and related analogs exploit replicative and checkpoint vulnerabilities to induce death of triple-negative breast cancer cells Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-B103 |
0.829 |
|
| 2018 |
Liang X, Wang B, Chen C, Wang A, Hu C, Zou F, Yu K, Liu Q, Li F, Hu Z, Lu T, Wang J, Wang L, Weisberg E, Li L, ... ... Liu Q, et al. Discovery of N-(4-(6-acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent Fms-like Tyrosine Kinase 3 Internal Tandem Duplications (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. Journal of Medicinal Chemistry. PMID 30565931 DOI: 10.1021/Acs.Jmedchem.8B01594 |
0.57 |
|
| 2018 |
Liu X, Wang B, Chen C, Jiang Z, Hu C, Wu H, Zhang Y, Liu X, Wang W, Wang J, Hu Z, Wang A, Huang T, Liu Q, Wang W, ... ... Liu Q, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. European Journal of Medicinal Chemistry. 160: 61-81. PMID 30317026 DOI: 10.1016/J.Ejmech.2018.10.007 |
0.509 |
|
| 2018 |
Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, ... ... Liu Q, et al. Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor. European Journal of Medicinal Chemistry. 158: 896-916. PMID 30253346 DOI: 10.1016/J.Ejmech.2018.09.025 |
0.562 |
|
| 2018 |
Deng K, Shen J, Wang W, Li M, Li H, Chen C, Zhao H, Zhang M, Xue T, Liu Q, Lui VWY, Hong B, Lin W. Sodium chloride (NaCl) potentiates digoxin-induced anti-tumor activity in small cell lung cancer. Cancer Biology & Therapy. 1-13. PMID 30183476 DOI: 10.1080/15384047.2018.1504723 |
0.413 |
|
| 2018 |
Liang X, Li F, Chen C, Jiang Z, Wang A, Liu X, Ge J, Hu Z, Yu K, Wang W, Zou F, Liu Q, Wang B, Wang L, Zhang S, ... ... Liu Q, et al. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. European Journal of Medicinal Chemistry. 156: 831-846. PMID 30053721 DOI: 10.1016/J.Ejmech.2018.07.036 |
0.57 |
|
| 2018 |
He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, Zhou R. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nature Communications. 9: 2550. PMID 29959312 DOI: 10.1038/S41467-018-04947-6 |
0.579 |
|
| 2018 |
Xue Y, Song P, Song Z, Wang A, Tong L, Geng MY, Ding J, Liu Q, Sun L, Xie H, Zhang A. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton's Tyrosine Kinase (BTK) Inhibitors. Journal of Medicinal Chemistry. PMID 29715023 DOI: 10.1021/Acs.Jmedchem.8B00441 |
0.48 |
|
| 2018 |
Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, ... ... Liu Q, et al. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. European Journal of Medicinal Chemistry. 150: 366-384. PMID 29544149 DOI: 10.1016/J.Ejmech.2018.03.003 |
0.537 |
|
| 2017 |
Yu K, Liu X, Jiang Z, Hu C, Zou F, Chen C, Ge J, Wu J, Liu X, Wang A, Wang W, Wang W, Qi Z, Wang B, Wang L, ... ... Liu Q, et al. Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs). Oncotarget. 8: 111110-111118. PMID 29340041 DOI: 10.18632/Oncotarget.22624 |
0.481 |
|
| 2017 |
Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, Wang A, Tao J, Wang C, Liu Q, Jin T, Jiang W, Deng X, Zhou R. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. The Journal of Experimental Medicine. PMID 29021150 DOI: 10.1084/Jem.20171419 |
0.622 |
|
| 2017 |
Wang A, Li X, Chen C, Wu H, Qi Z, Hu C, Yu K, Wu J, Liu J, Liu X, Hu Z, Wang W, Wang W, Wang W, Wang L, ... ... Liu Q, ... ... Liu Q, et al. Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d] pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML. Journal of Medicinal Chemistry. PMID 28956923 DOI: 10.1021/Acs.Jmedchem.7B00840 |
0.522 |
|
| 2017 |
Chen Y, Wu J, Wang A, Qi Z, Jiang T, Chen C, Zou F, Hu C, Wang W, Wu H, Hu Z, Wang W, Wang B, Wang L, Ren T, ... ... Liu Q, et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC. European Journal of Medicinal Chemistry. 139: 674-697. PMID 28850922 DOI: 10.1016/J.Ejmech.2017.08.035 |
0.503 |
|
| 2017 |
Wong KK, Liu Y, Li Y, Wang X, Liu F, Gao P, Quinn MM, Li F, Merlino AA, Benes CH, Liu Q, Gray NS. Gemcitabine and Chk1 inhibitor AZD7762 synergistically suppress the growth of Lkb1-deficient lung adenocarcinoma. Cancer Research. PMID 28754670 DOI: 10.1158/0008-5472.Can-17-0567 |
0.554 |
|
| 2017 |
Wang B, Deng Y, Chen Y, Yu K, Wang A, Liang Q, Wang W, Chen C, Wu H, Hu C, Miao W, Hur W, Wang W, Hu Z, Weisberg EL, ... ... Liu Q, et al. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. European Journal of Medicinal Chemistry. 137: 545-557. PMID 28628824 DOI: 10.1016/J.Ejmech.2017.06.016 |
0.631 |
|
| 2017 |
Hu C, Wang A, Wu H, Qi Z, Li X, Yan XE, Chen C, Yu K, Zou F, Wang W, Wang W, Wu J, Liu J, Wang B, Wang L, ... ... Liu Q, et al. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget. 8: 18359-18372. PMID 28407693 DOI: 10.18632/Oncotarget.15443 |
0.482 |
|
| 2017 |
Wu H, Huang Q, Qi Z, Chen Y, Wang A, Chen C, Liang Q, Wang J, Chen W, Dong J, Yu K, Hu C, Wang W, Liu X, Deng Y, ... ... Liu Q, et al. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Scientific Reports. 7: 466. PMID 28352114 DOI: 10.1038/S41598-017-00482-4 |
0.545 |
|
| 2017 |
Liang Y, de Wispelaere M, Carocci M, Liu Q, Wang J, Yang PL, Gray NS. Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent. Acs Medicinal Chemistry Letters. 8: 344-349. PMID 28337328 DOI: 10.1021/Acsmedchemlett.7B00008 |
0.587 |
|
| 2017 |
Zhao Z, Liu Q, Bliven S, Xie L, Bourne PE. Determining cysteines available for covalent inhibition across the human kinome. Journal of Medicinal Chemistry. PMID 28326775 DOI: 10.1021/Acs.Jmedchem.6B01815 |
0.46 |
|
| 2017 |
Liang Q, Chen Y, Yu K, Chen C, Zhang S, Wang A, Wang W, Wu H, Liu X, Wang B, Wang L, Hu Z, Wang W, Ren T, Zhang S, ... Liu Q, et al. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. European Journal of Medicinal Chemistry. 131: 107-125. PMID 28315597 DOI: 10.1016/J.Ejmech.2017.03.001 |
0.563 |
|
| 2017 |
Liu J, Yang X, Li B, Wang J, Wang W, Liu J, Liu Q, Zhang X. STK16 regulates actin dynamics to control Golgi organization and cell cycle. Scientific Reports. 7: 44607. PMID 28294156 DOI: 10.1038/Srep44607 |
0.415 |
|
| 2017 |
Wang A, Li X, Wu H, Zou F, Yan XE, Chen C, Hu C, Yu K, Wang W, Zhao P, Wu J, Qi Z, Wang W, Wang B, Wang L, ... ... Liu Q, et al. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode. Journal of Medicinal Chemistry. PMID 28282122 DOI: 10.1021/Acs.Jmedchem.6B01907 |
0.484 |
|
| 2017 |
Liang X, Lv F, Wang B, Yu K, Wu H, Qi Z, Jiang Z, Chen C, Wang A, Miao W, Wang W, Hu Z, Liu J, Liu X, Zhao Z, ... ... Liu Q, et al. Discovery of 2-((3-acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. Journal of Medicinal Chemistry. PMID 28140585 DOI: 10.1021/Acs.Jmedchem.6B01413 |
0.53 |
|
| 2016 |
Yang Y, Zhang Y, Yang L, Zhao L, Si L, Zhang H, Liu Q, Zhou J. Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity. Bioorganic Chemistry. PMID 28043720 DOI: 10.1016/J.Bioorg.2016.12.002 |
0.441 |
|
| 2016 |
de Wispelaere M, Carocci M, Liang Y, Liu Q, Sun E, Vetter ML, Wang J, Gray NS, Yang PL. Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Research. PMID 28034743 DOI: 10.1016/J.Antiviral.2016.12.017 |
0.531 |
|
| 2016 |
Wang Q, Liu F, Wang B, Zou F, Qi Z, Chen C, Yu K, Hu C, Qi S, Wang W, Hu Z, Liu J, Wang W, Wang L, Liang Q, ... ... Liu Q, et al. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. Journal of Medicinal Chemistry. PMID 27966954 DOI: 10.1021/Acs.Jmedchem.6B01290 |
0.55 |
|
| 2016 |
Wang A, Yan XE, Wu H, Wang W, Hu C, Chen C, Zhao Z, Zhao P, Li X, Wang L, Wang B, Ye Z, Wang J, Wang C, Zhang W, ... ... Liu Q, et al. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget. PMID 27626175 DOI: 10.18632/Oncotarget.11951 |
0.604 |
|
| 2016 |
Li B, Wang A, Liu J, Qi Z, Liu X, Yu K, Wu H, Chen C, Hu C, Wang W, Wu J, Hu Z, Ye L, Zou F, Liu F, ... ... Liu Q, et al. Discovery of N-((1-(4-(3-(3-((6,7-dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase. Journal of Medicinal Chemistry. PMID 27545040 DOI: 10.1021/Acs.Jmedchem.6B00902 |
0.547 |
|
| 2016 |
Liu X, Wang A, Liang X, Liu J, Zou F, Chen C, Zhao Z, Deng Y, Wu H, Qi Z, Wang B, Wang L, Liu F, Xu Y, Wang W, ... ... Liu Q, et al. Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies. Oncotarget. PMID 27447747 DOI: 10.18632/Oncotarget.10650 |
0.547 |
|
| 2016 |
Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, ... ... Liu Q, et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell. PMID 27397505 DOI: 10.1016/J.Cell.2016.06.017 |
0.638 |
|
| 2016 |
Liu F, Wang B, Wang Q, Qi Z, Chen C, Kong LL, Chen JY, Liu X, Wang A, Hu C, Wang W, Wang H, Wu F, Ruan Y, Qi S, ... ... Liu Q, et al. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML). Oncotarget. PMID 27322145 DOI: 10.18632/Oncotarget.10037 |
0.514 |
|
| 2016 |
Zhang L, Wang J, Wang H, Wang W, Li Z, Liu J, Yang X, Ji X, Luo Y, Hu C, Hou Y, He Q, Fang J, Wang J, Liu Q, et al. Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation. Oncotarget. PMID 27223425 DOI: 10.18632/Oncotarget.9479 |
0.394 |
|
| 2016 |
Wu H, Wang A, Qi Z, Li X, Chen C, Yu K, Zou F, Hu C, Wang W, Zhao Z, Wu J, Liu J, Liu X, Wang L, Wang W, ... ... Liu Q, et al. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia. PMID 27220667 DOI: 10.1038/Leu.2016.151 |
0.489 |
|
| 2016 |
Udayakumar D, Pandita RK, Horikoshi N, Liu Y, Liu Q, Wong KK, Hunt CR, Gray NS, Minna JD, Pandita TK, Westover KD. Torin2 Suppresses Ionizing Radiation-Induced DNA Damage Repair. Radiation Research. PMID 27135971 DOI: 10.1667/Rr14373.1 |
0.702 |
|
| 2016 |
Liu F, Wang J, Yang X, Li B, Wu H, Qi S, Chen C, Liu X, Yu K, Wang W, Zhao Z, Wang A, Chen YF, Wang L, Gray NS, ... ... Liu Q, et al. Discovery of a Highly Selective STK16 Kinase Inhibitor. Acs Chemical Biology. PMID 27082499 DOI: 10.1021/Acschembio.6B00250 |
0.663 |
|
| 2016 |
Liu X, Wang A, Liang X, Chen C, Liu J, Zhao Z, Wu H, Deng Y, Wang L, Wang B, Wu J, Liu F, Fernandes SM, Adamia S, Stone RM, ... ... Liu Q, et al. Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignances. Oncotarget. PMID 27081697 DOI: 10.18632/Oncotarget.8702 |
0.48 |
|
| 2016 |
Wang Q, Liu F, Wang B, Zou F, Chen C, Liu X, Wang A, Qi S, Wang W, Qi Z, Zhao Z, Hu Z, Wang W, Wang L, Zhang S, ... ... Liu Q, et al. Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs). Journal of Medicinal Chemistry. PMID 27077705 DOI: 10.1021/Acs.Jmedchem.6B00200 |
0.544 |
|
| 2016 |
Li Z, Ji X, Wang W, Liu J, Liang X, Wu H, Liu J, Eggert US, Liu Q, Zhang X. Ammonia Induces Autophagy through Dopamine Receptor D3 and MTOR. Plos One. 11: e0153526. PMID 27077655 DOI: 10.1371/Journal.Pone.0153526 |
0.365 |
|
| 2016 |
Wang A, Wu H, Chen C, Hu C, Qi Z, Wang W, Yu K, Liu X, Zou F, Zhao Z, Wu J, Liu J, Liu F, Wang L, Stone RM, ... ... Liu Q, et al. Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML. Oncotarget. PMID 27074558 DOI: 10.18632/Oncotarget.8675 |
0.473 |
|
| 2016 |
Liang X, Liu X, Wang B, Zou F, Wang A, Qi S, Chen C, Zhao Z, Wang W, Qi Z, Lv F, Hu Z, Wang L, Zhang S, Liu Q, et al. Discovery of 2-((3-amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a potent, selective and orally available BCR-ABL/SRC/p38 kinase inhibitor for Chronic Myeloid Leukemia. Journal of Medicinal Chemistry. PMID 26789553 DOI: 10.1021/Acs.Jmedchem.5B01618 |
0.465 |
|
| 2016 |
Luo Y, Ji X, Liu J, Li Z, Wang W, Chen W, Wang J, Liu Q, Zhang X. Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol. Bioelectrochemistry (Amsterdam, Netherlands). 109: 31-40. PMID 26775206 DOI: 10.1016/J.Bioelechem.2016.01.001 |
0.358 |
|
| 2015 |
Neel VA, Todorova K, Wang J, Kwon E, Kang M, Liu Q, Gray N, Lee SW, Mandinova A. Sustained Akt activity is required to maintain cell viability in seborrheic keratosis, a benign epithelial tumor. The Journal of Investigative Dermatology. PMID 26739095 DOI: 10.1016/J.Jid.2015.12.023 |
0.635 |
|
| 2015 |
Li X, Wang A, Yu K, Qi Z, Chen C, Wang W, Hu C, Wu H, Wu J, Zhao Z, Liu J, Zou F, Wang L, Wang B, Wang W, ... ... Liu Q, et al. Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. Journal of Medicinal Chemistry. PMID 26630553 DOI: 10.1021/Acs.Jmedchem.5B01611 |
0.57 |
|
| 2015 |
Wu R, Chen H, Ma J, He Q, Huang Q, Liu Q, Li M, Yuan Z. c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death. Cell Death and Differentiation. PMID 26517532 DOI: 10.1038/Cdd.2015.135 |
0.34 |
|
| 2015 |
Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS. Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer. Acs Chemical Biology. PMID 26390252 DOI: 10.1021/Acschembio.5B00655 |
0.798 |
|
| 2015 |
Wu H, Wang A, Zhang W, Wang B, Chen C, Wang W, Hu C, Ye Z, Zhao Z, Wang L, Li X, Yu K, Liu J, Wu J, Yan XE, ... ... Liu Q, et al. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. Oncotarget. PMID 26375053 DOI: 10.18632/Oncotarget.5182 |
0.603 |
|
| 2015 |
Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, ... ... Liu Q, et al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. PMID 26165234 DOI: 10.1038/Leu.2015.180 |
0.686 |
|
| 2015 |
Wu H, Hu C, Wang A, Weisberg EL, Wang W, Chen C, Zhao Z, Yu K, Liu J, Wu J, Nonami A, Wang L, Wang B, Stone RM, Liu S, ... ... Liu Q, et al. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia. PMID 26139428 DOI: 10.1038/Leu.2015.175 |
0.344 |
|
| 2015 |
Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase. Plos One. 10: e0128364. PMID 26046350 DOI: 10.1371/Journal.Pone.0128364 |
0.74 |
|
| 2015 |
Nonami A, Sattler M, Weisberg E, Liu Q, Zhang J, Patricelli MP, Christie AL, Saur AM, Kohl NE, Kung AL, Yoon H, Sim T, Gray NS, Griffin JD. Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. Blood. 125: 3133-43. PMID 25833960 DOI: 10.1182/Blood-2014-12-615906 |
0.66 |
|
| 2015 |
Weisberg E, Nonami A, Chen Z, Liu F, Zhang J, Sattler M, Nelson E, Cowens K, Christie AL, Mitsiades C, Wong KK, Liu Q, Gray N, Griffin JD. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia. 29: 27-37. PMID 24791855 DOI: 10.1038/Leu.2014.149 |
0.579 |
|
| 2015 |
Udayakumar D, Pandita RK, Horikoshi N, Hunt CR, Liu Q, Wong K, Gray NS, Pandita TK, Westover KD. Abstract 2852: Torin2 suppresses ionizing radiation induced DNA damage repair Cancer Research. 75: 2852-2852. DOI: 10.1158/1538-7445.Am2015-2852 |
0.616 |
|
| 2014 |
Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, Frumm S, Liu QS, Christie AL, Sanda T, Chesler L, Kung AL, Gray NS, Stegmaier K, George RE. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget. 5: 8737-49. PMID 25228590 DOI: 10.18632/Oncotarget.2372 |
0.583 |
|
| 2014 |
Weisberg E, Nonami A, Chen Z, Nelson E, Chen Y, Liu F, Cho H, Zhang J, Sattler M, Mitsiades C, Wong KK, Liu Q, Gray NS, Griffin JD. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5483-95. PMID 25186968 DOI: 10.1158/1078-0432.Ccr-14-0902 |
0.476 |
|
| 2014 |
Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q, Gray NS. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? Acs Chemical Biology. 9: 1230-41. PMID 24730530 DOI: 10.1021/Cb500129T |
0.627 |
|
| 2014 |
Codeluppi S, Fernandez-Zafra T, Sandor K, Kjell J, Liu Q, Abrams M, Olson L, Gray NS, Svensson CI, Uhlén P. Interleukin-6 secretion by astrocytes is dynamically regulated by PI3K-mTOR-calcium signaling. Plos One. 9: e92649. PMID 24667246 DOI: 10.1371/Journal.Pone.0092649 |
0.435 |
|
| 2014 |
Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, ... ... Liu Q, et al. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. Acs Chemical Biology. 9: 1086-91. PMID 24556163 DOI: 10.1021/Cb4008524 |
0.638 |
|
| 2014 |
Kim H, Tan L, Weisberg EL, Liu F, Canning P, Choi H, Ezell S, Zhao Z, Wu H, Wang J, Mandinova A, Bullock AN, Liu Q, Lee SW, Gray NS. Correction to Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor Acs Chemical Biology. 9: 840-840. DOI: 10.1021/Cb5000949 |
0.538 |
|
| 2013 |
Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. Acs Chemical Biology. 8: 2145-50. PMID 23899692 DOI: 10.1021/Cb400430T |
0.671 |
|
| 2013 |
Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, Gray NS, Lindquist S. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nature Biotechnology. 31: 630-7. PMID 23811600 DOI: 10.1038/Nbt.2620 |
0.63 |
|
| 2013 |
Liao RG, Jung J, Tchaicha J, Wilkerson MD, Sivachenko A, Beauchamp EM, Liu Q, Pugh TJ, Pedamallu CS, Hayes DN, Gray NS, Getz G, Wong KK, Haddad RI, Meyerson M, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Research. 73: 5195-205. PMID 23786770 DOI: 10.1158/0008-5472.Can-12-3950 |
0.537 |
|
| 2013 |
Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, et al. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discovery. 3: 870-9. PMID 23715154 DOI: 10.1158/2159-8290.Cd-13-0015 |
0.617 |
|
| 2013 |
Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, ... ... Liu Q, et al. Discovery of a selective irreversible BMX inhibitor for prostate cancer. Acs Chemical Biology. 8: 1423-8. PMID 23594111 DOI: 10.1021/Cb4000629 |
0.631 |
|
| 2013 |
Jain R, Jain D, Liu Q, Bartosinska B, Wang J, Schumann D, Kauschke SG, Eickelmann P, Piemonti L, Gray NS, Lammert E. Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets. Diabetologia. 56: 1350-5. PMID 23475368 DOI: 10.1007/S00125-013-2877-1 |
0.462 |
|
| 2013 |
Liu Q, Sabnis Y, Zhao Z, Zhang T, Buhrlage SJ, Jones LH, Gray NS. Developing irreversible inhibitors of the protein kinase cysteinome. Chemistry & Biology. 20: 146-59. PMID 23438744 DOI: 10.1016/J.Chembiol.2012.12.006 |
0.647 |
|
| 2013 |
Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N. Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. Plos One. 8: e56473. PMID 23437141 DOI: 10.1371/Journal.Pone.0056473 |
0.666 |
|
| 2013 |
Liu Q, Xu C, Kirubakaran S, Zhang X, Hur W, Liu Y, Kwiatkowski NP, Wang J, Westover KD, Gao P, Ercan D, Niepel M, Thoreen CC, Kang SA, Patricelli MP, et al. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Research. 73: 2574-86. PMID 23436801 DOI: 10.1158/0008-5472.Can-12-1702 |
0.825 |
|
| 2013 |
Giubellino A, Bullova P, Nölting S, Turkova H, Powers JF, Liu Q, Guichard S, Tischler AS, Grossman AB, Pacak K. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology. 154: 646-55. PMID 23307788 DOI: 10.1210/En.2012-1854 |
0.507 |
|
| 2013 |
Nonami A, Sattler M, Weisberg EL, Zhang J, Liu Q, Patricell M, Yoon H, Christie AL, Sauer AM, Kohl N, Kung AL, Sim T, Gray NS, Griffin JD. Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells Blood. 122: 169-169. DOI: 10.1182/Blood.V122.21.169.169 |
0.642 |
|
| 2013 |
Bhatnagar N, Luther W, Sharma B, Liu Q, Gray N, George RE. Abstract 4454: The AXL tyrosine kinase receptor contributes to ALK-inhibitor resistance in neuroblastoma. Cancer Research. 73: 4454-4454. DOI: 10.1158/1538-7445.Am2013-4454 |
0.607 |
|
| 2012 |
Rodrigues FS, Yang X, Nikaido M, Liu Q, Kelsh RN. A simple, highly visual in vivo screen for anaplastic lymphoma kinase inhibitors. Acs Chemical Biology. 7: 1968-74. PMID 22985331 DOI: 10.1021/Cb300361A |
0.587 |
|
| 2012 |
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, ... Liu Q, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 22: 117-30. PMID 22789543 DOI: 10.1016/J.Ccr.2012.06.001 |
0.592 |
|
| 2012 |
Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, Riddle S, Benes C, Eck M, Roberts T, Gray N, Zhao J. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discovery. 2: 425-33. PMID 22588880 DOI: 10.1158/2159-8290.Cd-12-0003 |
0.641 |
|
| 2012 |
Liu Q, Ren T, Fresques T, Oppliger W, Niles BJ, Hur W, Sabatini DM, Hall MN, Powers T, Gray NS. Selective ATP-competitive inhibitors of TOR suppress rapamycin-insensitive function of TORC2 in Saccharomyces cerevisiae. Acs Chemical Biology. 7: 982-7. PMID 22496512 DOI: 10.1021/Cb300058V |
0.667 |
|
| 2012 |
Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Leukemia. 26: 2233-44. PMID 22469781 DOI: 10.1038/Leu.2012.96 |
0.663 |
|
| 2012 |
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483: 570-5. PMID 22460902 DOI: 10.1038/Nature11005 |
0.652 |
|
| 2012 |
Liu J, Hu Y, Waller DL, Wang J, Liu Q. Natural products as kinase inhibitors. Natural Product Reports. 29: 392-403. PMID 22231144 DOI: 10.1039/C2Np00097K |
0.484 |
|
| 2012 |
Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. The Journal of Biological Chemistry. 287: 9742-52. PMID 22223645 DOI: 10.1074/Jbc.M111.304485 |
0.826 |
|
| 2012 |
Liu Q, Kang SA, Thoreen CC, Hur W, Wang J, Chang JW, Markhard A, Zhang J, Sim T, Sabatini DM, Gray NS. Development of ATP-competitive mTOR inhibitors. Methods in Molecular Biology (Clifton, N.J.). 821: 447-60. PMID 22125084 DOI: 10.1007/978-1-61779-430-8_29 |
0.797 |
|
| 2012 |
Liu J, Liu F, L. Waller D, Wang J, Liu Q. Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies Current Angiogenesis. 1: 335-346. DOI: 10.2174/2211552811201040335 |
0.367 |
|
| 2012 |
Azarova AM, Bhatnagar N, Olsen-Drake L, Ross K, Frumm S, Liu Q, Christie A, Sanda T, Rodig SJ, Christensen JG, Kung AL, Gray N, Stegmaier K, George RE. Abstract 2935: The ATP-competitive mTOR inhibitor Torin2 enhances sensitivity of the ALK F1174L mutation to crizotinib in neuroblastoma Cancer Research. 72: 2935-2935. DOI: 10.1158/1538-7445.Am2012-2935 |
0.637 |
|
| 2012 |
Liao R, Hammerman P, Sivachenko A, Greulich H, Getz G, Liu Q, Gray N, Meyerson M. Abstract 2: FGFR3 as a therapeutic target in squamous cell lung carcinoma Cancer Research. 72: 2-2. DOI: 10.1158/1538-7445.Am2012-2 |
0.523 |
|
| 2012 |
Liao RG, Hammerman P, Sivachencko A, Greulich H, Getz G, Liu Q, Gray N, Meyerson M. Abstract B13: FGFR2 as a therapeutic target in squamous cell lung carcinoma Clinical Cancer Research. 18: B13-B13. DOI: 10.1158/1078-0432.12Aacriaslc-B13 |
0.528 |
|
| 2011 |
Yang PL, Gao M, Lin K, Liu Q, Villareal VA. Anti-HCV drugs in the pipeline. Current Opinion in Virology. 1: 607-16. PMID 22440918 DOI: 10.1016/J.Coviro.2011.10.019 |
0.343 |
|
| 2011 |
Obara I, Tochiki KK, Géranton SM, Carr FB, Lumb BM, Liu Q, Hunt SP. Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice. Pain. 152: 2582-95. PMID 21917376 DOI: 10.1016/J.Pain.2011.07.025 |
0.353 |
|
| 2011 |
Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Choi HG, Waller DL, Sim T, Sabatini DM, Gray NS. Discovery and optimization of potent and selective benzonaphthyridinone analogs as small molecule mTOR inhibitors with improved mouse microsome stability. Bioorganic & Medicinal Chemistry Letters. 21: 4036-40. PMID 21621413 DOI: 10.1016/J.Bmcl.2011.04.129 |
0.763 |
|
| 2011 |
Hu Y, Liu J, Wang J, Liu Q. The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radical Biology & Medicine. 51: 250-6. PMID 21569839 DOI: 10.1016/J.Freeradbiomed.2011.04.034 |
0.311 |
|
| 2011 |
Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature Chemical Biology. 7: 203-5. PMID 21378983 DOI: 10.1038/Nchembio.538 |
0.688 |
|
| 2011 |
Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM, Gray NS. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. Journal of Medicinal Chemistry. 54: 1473-80. PMID 21322566 DOI: 10.1021/Jm101520V |
0.803 |
|
| 2011 |
Liu Q, Zhou D, Shiotani B, Gray NS, Elledge SJ, Zou L. Abstract 1358: Discovery and optimization of potent and selective benzonaphthyridinone analogs as dual mTOR/ATR small molecular inhibitors for treatment of cancer Cancer Research. 71: 1358-1358. DOI: 10.1158/1538-7445.Am2011-1358 |
0.575 |
|
| 2010 |
Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. Journal of Medicinal Chemistry. 53: 7146-55. PMID 20860370 DOI: 10.1021/Jm101144F |
0.822 |
|
| 2009 |
Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discovery Today. Therapeutic Strategies. 6: 47-55. PMID 20622997 DOI: 10.1016/J.Ddstr.2009.12.001 |
0.798 |
|
| 2009 |
Choi Y, Syeda F, Walker JR, Finerty PJ, Cuerrier D, Wojciechowski A, Liu Q, Dhe-Paganon S, Gray NS. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 4467-70. PMID 19553108 DOI: 10.1016/J.Bmcl.2009.05.029 |
0.631 |
|
| 2009 |
Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 81-9. PMID 19467916 DOI: 10.1016/J.Drup.2009.04.001 |
0.644 |
|
| 2009 |
Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The Journal of Biological Chemistry. 284: 8023-32. PMID 19150980 DOI: 10.1074/Jbc.M900301200 |
0.814 |
|
| Show low-probability matches. |